NONCLINICAL STUDIES SUBCOMMITTEE OF THE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE

March 9, 2000 CDER Advisory Committee Conference Room 5630 Fishers Lane Rockville, MD

AGENDA

8:30	Call to Order/Chairman's Remarks/ Conflict of Interest	John Doull, M.D., Ph.D. (Chair)
8:45	FDA Objectives	James MacGregor, Ph.D.
9:00	Biomarkers, Introduction	Frank Sistare, Ph.D.
9:05	NIH Perspective on Biomarkers	Gregory Downing, Ph.D.
9:25	Establishing Biomarkers of Toxicity for Safety Assessmental A Focus on Cardiac and Skeletal Muscle Toxicity	nt Malcolm York, M.Phil.
9:50	Proteomics and Safety Biomarker Discovery	Gordon Holt, Ph.D.
10:10	Proteomics Technology	Leigh Anderson, Ph.D.
J:30	Break	
10:45	Applications of SELDI to Protein Biomarker Discovery Strategies	E. Chip Petricoin, Ph.D.
11:05	Applications of Gene Expression Analyses in Peripheral Blood Cells to Safety Assessment	Spencer Farr, Ph.D.
11:25	TaqMan Gene Expression Arrays for Accurate Quantification of Toxicity Targets	Frederico Goodsaid, Ph.D.
11:45	Recommendations for Biomarkers Projects	Frank Sistare, Ph.D.
12:00	Subcommittee Discussion	
12:30	Lunch	
1:30	Open Public Hearing	
2:30	Subcommittee Discussion	

3:00	Micro-PET: Experiences with Small Animal Imaging	Simon Cherry, Ph.D.
20:ر	Break	
5	NIH/NCI Initiatives to Stimulate Applications of Imaging Technology	James Tatum, M.D.
3:55	Proposal to Form Expert Working Group on Imaging	Jerry Collins, Ph.D.
4:10	Subcommittee Discussion	
	Adjourn	